Acute moderate to severe pain

Active Ingredient: Sufentanil

Indication for Sufentanil

Population group: only adults (18 years old or older)
Therapeutic intent: Curative procedure

Sufentanil is indicated for the management of acute moderate to severe pain in adult patients.

For this indication, competent medicine agencies globally authorize below treatments:

30 ug/dose as needed by the patient, but no more than once every hour, resulting in a maximum dose of 720 micrograms/day

For:

Dosage regimens

Sublingual, 30 micrograms sufentanil, 1 to 24 doses in total, over the duration of at least 1 hour.

Detailed description

Sufentanil is to be administered by a healthcare professional in a medically monitored setting only. A medically monitored setting must have equipment and personnel trained to detect and manage hypoventilation, and availability of supplemental oxygen and opioid antagonists, such as naloxone. Sufentanil should only be prescribed and administered by healthcare professionals who are experienced in the management of opioid therapy; particularly opioid adverse reactions, such as respiratory depression.

Sufentanil is provided in a disposable single-dose applicator, to be administered by a healthcare provider as needed by the individual patient, but no more than once every hour, resulting in a maximum dose of 720 micrograms/day. Patients with a higher pain intensity at one hour after sufentanil treatment was initiated required more frequent redosing compared to patients with lower pain intensity scores at one hour.

Sufentanil should not be used beyond 48 hours.

Elderly

No specific dose adjustment is required in elderly patients. However, elderly patients should be observed closely for adverse reactions of sufentanil.

Dosage considerations

The dispensed sublingual tablet should dissolve under the tongue and should not be chewed or swallowed. If swallowed, the oral bioavailability of sufentanil is only 9% which would result in a sub-therapeutic dose. Patients should not eat or drink and should minimise talking for 10 minutes after each dose of sufentanil. In the case of an excessive dry mouth, patients may be given ice cubes.

Active ingredient

Sufentanil

Sufentanil is a synthetic, potent opioid with highly selective binding to μ-opioid receptors. Sufentanil acts as a full agonist in μ-opioid receptors. Sufentanil does not induce histamine release.

Read more about Sufentanil

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.